Form 4: Protagonist Therapeutics CEO Sells 25,000 Shares Under 10b5-1 Trading Plan

Protagonist Therapeutics' CEO, Dinesh V. Patel, Ph.D., sold 25,000 shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Dinesh V. Patel, Ph.D., the President and CEO of Protagonist Therapeutics, Inc., reported the sale of 25,000 shares of common stock on April 1, 2024.
• The sale was executed under a Rule 10b5-1 trading plan adopted on March 20, 2023.
• The shares were sold at a weighted average price of $28.31, with individual transaction prices ranging from $27.69 to $28.77.
• Following the transaction, Patel directly owns 549,590 shares of Protagonist Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan. It doesn't necessarily indicate a positive or negative outlook for the company.

Industry Context

Insider selling can sometimes be viewed negatively by the market, but sales under pre-arranged 10b5-1 plans are generally seen as less concerning as they are planned in advance and not based on current inside information.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is mitigated by the fact that it was conducted under a pre-arranged trading plan.

Key Dates